Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
复制标题
DOI：
10.1182/blood.v93.5.1697.405a17_1697_1706
复制
发表时间：
1999-03-01
期刊：
影响因子：
20.3
通讯作者：
Mundy, GR
中科院分区：
文献类型：
--
作者：
Dallas, SL;Garrett, IR;Mundy, GR
我们在人类骨髓瘤骨病的小鼠模型中确定了有效的双膦酸伊班磷酸酯的效果。在这个模型中，通过尾静脉接种骨髓瘤细胞后，小鼠出现了典型的人类疾病的骨损伤。伊班磷酸钠(每只小鼠每天4微克)治疗显著减少了骨髓瘤荷瘤小鼠溶骨性骨损伤的发生。然而，伊班磷酸钠并没有阻止小鼠的后肢瘫痪，也没有对存活率产生可检测到的影响。通过骨髓、肝脏和脾中骨髓瘤细胞的形态测量或血清IgG2b水平的测量，伊班磷酸钠对总的骨髓瘤细胞负荷没有显著影响。这些结果支持双膦酸盐可能对治疗骨髓瘤相关的骨破坏有用的临床发现，但也表明还需要其他治疗方法来减少肿瘤生长。(C)1999年由美国血液病学会主办。
We determined the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone disease. In this model, bone lesions typical of the human disease develop in mice following inoculation of myeloma cells via the tail vein. Treatment with ibandronate (4 mu g per mouse per day) significantly reduced the occurrence of osteolytic bone lesions in myeloma-bearing mice. However, ibandronate did not prevent the mice from developing hindlimb paralysis and did not produce a detectable effect onsurvival. There was no significant effect of ibandronate on total myeloma cell burden, as assessed by morphometric measurements of myeloma cells in the bone marrow, liver, and spleen, or by measurement of serum IgG2b levels. These results support clinical findings that bisphosphonates may be useful for the treatment of myeloma-associated bone destruction, but suggest that other therapies are also required to reduce tumor growth. (C) 1999 by The American Society of Hematology.